Wave Life Sciences
WVE
3.54
+0.02
+0.57%
Wave Life Sciences
US · WVE
#3515 by market cap
Listed 2015
3.54
+0.02
+0.57%
Live - 5344 symbols - heartbeat 282s ago
· 2026-10-08 09:02
Pre-market
3.54
0.00%
After-hours
3.54
-0.06%
- Market cap
- 697.55M
- P/E (TTM)i
- -3.28
- P/Bi
- 1.54
- EPSi
- -1.21
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on WVE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.51, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -60.55% YoY
Margins
- Operating margin
- -504.09%
- Net margin
- -478.33%
Key ratios & quality
- Altman Z-Scorei
- 0.51
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.41M | 15.98M | 20.08M | 40.96M | 3.65M | 113.31M | 108.30M | 42.73M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 39.51M | 48.87M | 42.51M | 46.11M | 50.51M | 51.29M | 59.02M | 75.33M |
| Research & development | 134.43M | 175.43M | 130.94M | 121.88M | 115.86M | 130.01M | 159.68M | 182.78M |
| Operating profit | -159.52M | -208.32M | -153.38M | -127.02M | -162.72M | -68.00M | -110.40M | -215.38M |
| Pretax profit | -146.58M | -193.64M | -150.75M | -122.45M | -161.14M | -58.19M | -97.01M | -204.38M |
| Tax | 69.00K | 0 | -841.00K | -204.00K | 681.00K | -677.00K | 0 | 0 |
| Net profit | -146.65M | -193.64M | -149.91M | -122.25M | -161.82M | -57.51M | -97.01M | -204.38M |
| Basic EPS | -5 | -6 | -4 | -2 | -2 | -1 | -1 | -1 |
| Diluted EPS | -5.06 | -5.72 | -3.82 | -2.36 | -2.05 | -0.54 | -0.70 | -1.21 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 9.18M | 8.70M | 7.61M | 17.25M | 38.25M | 2.27M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 18.36M | 17.99M | 18.09M | 20.90M | 22.10M | 24.78M |
| Research & development | 40.62M | 43.47M | 45.87M | 52.81M | 47.44M | 51.29M |
| Operating profit | -49.80M | -52.76M | -56.35M | -56.47M | -31.30M | -73.80M |
| Pretax profit | -46.88M | -50.47M | -53.85M | -53.18M | -26.09M | -69.36M |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -46.88M | -50.47M | -53.85M | -53.18M | -26.09M | -69.36M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.29 | -0.31 | -0.32 | -0.30 | -0.13 | -0.34 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 202.27M | 185.48M | 230.04M | 162.56M | 98.54M | 235.37M | 320.39M | 614.81M |
| Cash & ST investments | 174.82M | 147.16M | 184.50M | 150.56M | 88.50M | 200.35M | 302.08M | 602.07M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 295.94M | 284.25M | 279.24M | 207.01M | 146.39M | 274.95M | 352.21M | 638.50M |
| Total current liabilities | 130.04M | 118.15M | 121.04M | 64.20M | 71.52M | 186.44M | 110.95M | 95.07M |
| Short-term debt | 1.16M | 3.24M | 3.71M | 4.96M | 5.50M | 6.71M | 7.64M | 8.36M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 222,592,000.00 | 220,518,000.00 | 196,460,000.00 | 174,509,000.00 | 191,477,000.00 | 235,319,000.00 | 142,692,000.00 | 120,142,000.00 |
| Total equity | 73.35M | 63.73M | 82.78M | 32.50M | -45.09M | 39.63M | 209.52M | 518.36M |
| Retained earnings | -339.72M | -533.36M | -683.27M | -805.51M | -967.34M | -1.02B | -1.12B | -1.33B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 257.98M | 223.56M | 215.49M | 614.81M | 561.27M | 507.51M |
| Cash & ST investments | 243.08M | 208.48M | 196.22M | 602.07M | 544.59M | 490.60M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 288.34M | 252.36M | 241.38M | 638.50M | 583.54M | 558.32M |
| Total current liabilities | 87.37M | 87.41M | 85.90M | 95.07M | 49.83M | 50.82M |
| Short-term debt | 7.88M | 8.14M | 8.39M | 8.36M | 8.33M | 3.51M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 116,540,000.00 | 113,089,000.00 | 116,829,000.00 | 120,142,000.00 | 71,814,000.00 | 104,801,000.00 |
| Total equity | 171.80M | 139.27M | 124.55M | 518.36M | 511.73M | 453.52M |
| Retained earnings | -1.17B | -1.22B | -1.27B | -1.33B | -1.35B | -1.42B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -22.86M | -188.23M | -115.98M | -88.99M | -127.78M | -19.43M | -151.03M | -187.49M |
| Depreciation & amortization | 5.58M | 9.20M | 9.98M | 9.84M | 10.11M | 9.21M | 8.66M | 8.85M |
| Free cash flow | -32.80M | -192.15M | -117.32M | -89.55M | -129.14M | -20.55M | -151.96M | -188.21M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 60.00M | 161.79M | 153.63M | 54.97M | 52.33M | 131.28M | 236.18M | 472.49M |
| Ending cash balance | 178.44M | 150.81M | 188.15M | 154.22M | 92.16M | 204.05M | 305.84M | 605.87M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -63.04M | -46.01M | -44.67M | -33.78M | -59.55M | -53.58M |
| Depreciation & amortization | 2.16M | 2.20M | 2.23M | 2.26M | 2.31M | 2.37M |
| Free cash flow | -63.20M | -46.32M | -44.91M | -33.78M | -59.99M | -54.47M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 1.26M | 11.10M | 30.21M | 429.91M | 0 | 0 |
| Ending cash balance | 246.85M | 212.27M | 200.01M | 605.87M | 548.41M | 371.82M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -137.60 | -282.52 | -204.64 | -212.09 | -- | -- | -77.87 | -56.16 |
| ROA %i | -61.39 | -66.75 | -53.21 | -50.28 | -91.58 | -27.30 | -30.94 | -41.26 |
| ROIC %i | -129.20 | -215.12 | -143.89 | -140.11 | -- | -- | -63.27 | -53.01 |
| 5-year avg ROE %i | -- | -111.83 | -147.56 | -182.26 | -- | -- | -- | -- |
| EBIT margin %i | -1,106.72 | -1,303.37 | -763.94 | -310.07 | -4,459.30 | -60.01 | -101.94 | -504.09 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.56 | 1.57 | 1.90 | 2.53 | 1.38 | 1.26 | 2.89 | 6.47 |
| Quick ratioi | 1.42 | 1.41 | 1.77 | 2.35 | 1.24 | 1.19 | 2.74 | 6.35 |
| Debt / assetsi | 3.52 | 11.45 | 10.49 | 14.45 | 25.70 | 11.68 | 7.21 | 2.78 |
| LT debt / equityi | 12.61 | 45.98 | 30.92 | 76.79 | -- | 64.10 | 8.48 | 1.81 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 356.02 | 144.61 | 72.77 | 41.65 | -38.88 | 78.04 | 38.28 | 127.08 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -113.93 | -191.29 | -91.62 | -56.16 | -53.72 | -68.31 |
| ROA %i | -42.91 | -56.32 | -40.66 | -41.26 | -42.11 | -49.95 |
| ROIC %i | -89.39 | -139.37 | -77.89 | -53.01 | -50.80 | -61.53 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -119.83 | -152.76 | -124.46 | -504.09 | -274.21 | -333.36 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.95 | 2.56 | 2.51 | 6.47 | 11.26 | 9.99 |
| Quick ratioi | 2.78 | 2.40 | 2.40 | 6.35 | 10.93 | 9.67 |
| Debt / assetsi | 8.18 | 8.60 | 8.19 | 2.78 | 2.69 | 7.81 |
| LT debt / equityi | 9.15 | 9.75 | 9.14 | 1.81 | 1.44 | 8.84 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Developing its proprietary Ribonucleic acid (RNA) medicines platform, PRISM, to develop and100.00%
Quote time 2026-10-08 09:02:42 · For reference only, not investment advice and not tailored to your situation.